Clinical ResearchHeart FailureComparison of Midregional Pro-Atrial and B-Type Natriuretic Peptides in Chronic Heart Failure: Influencing Factors, Detection of Left Ventricular Systolic Dysfunction, and Prediction of Death
Heart Failure
Under an Elsevier user license
open archive
Key Words
chronic heart failure
natriuretic peptides
prognosis
Abbreviations and Acronyms
ANP
atrial natriuretic peptide
AUC
area under curve
BMI
body mass index
BNP
B-type natriuretic peptide
GFR
glomerular filtration rate
HF
heart failure
LVEF
left ventricular ejection fraction
MR-proANP
midregional pro-atrial natriuretic peptide
NT-proANP
amino-terminal pro-atrial natriuretic peptide
NT-proBNP
amino-terminal pro–B-type natriuretic peptide
NYHA
New York Heart Association
PEV
proportion of explained variation
ROC
receiver-operating characteristic
Cited by (0)
Dr. Bergmann is a member of the board of directors of and holds ownership in B.R.A.H.M.S. AG (MR-proANP). Drs. Struck and Morgenthaler are employees of B.R.A.H.M.S. AG. Drs. Bergmann and Struck hold patent rights to MR-proANP.
Copyright © 2009 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.